Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma

Journal of Gene Medicine

Volumn 15, Issue 3-4, 2013, Pages 134-141

  de Jonge, Jonas ^a,b   Berghauser Pont, Lotte M E ^a   Idema, Sander ^b   Kloezeman, Jenneke J ^a   Noske, David ^b   Dirven, Clemens M F ^a   Lamfers, Martine L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Delta24 RGD; Glioblastoma; Levetiracetam; Oncolytic virus; Phenytoin; Valproic acid

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; ETIRACETAM; LUCIFERASE; ONCOLYTIC ADENOVIRUS; PHENYTOIN; VALPROIC ACID;

ADENOVIRUS INFECTION; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DILUTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; GLIOBLASTOMA; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; PROGENY; SEIZURE; VIRUS INFECTIVITY;

ADENOVIRIDAE; ANTICONVULSANTS; CELL LINE, TUMOR; CELL SURVIVAL; GLIOMA; HUMANS; INHIBITORY CONCENTRATION 50; LUCIFERASES; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PHENYTOIN; PIRACETAM; VALPROIC ACID;

ADENOVIRIDAE;

EID: 84876721330     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2703     Document Type: Article

References (38)

1. Parato KA, Senger D, Forsyth PA, et al. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-976.
2. Bauerschmitz GJ, Kanerva A, Wang M, et al. Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int J Cancer 2004; 111: 303-309.
3. Jiang H, Gomez-Manzano C, Lang FF, et al. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 2009; 9: 422-427.
4. Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652-660.
5. Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumour stem cells: role of autophagic cell death. J Natl Cancer Inst 2007; 99: 1410-1414.
6. Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62: 5736-5742.
7. Peng Y, Woods RG, Beamish H, et al. Deficiency in the catalytic subunit of DNA-dependent protein kinase causes down-regulation of ATM. Cancer Res 2005; 65: 1670-1677.
8. Mahfouz S, Aziz AA, Gabal SM, et al. Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med 2008; 10: 41.
9. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
10. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1 A mutant that demonstrates potent and selective systemic anti-tumoural efficacy. Nat Med 2000; 6: 1134-1139.
11. Fuxe J, Liu L, Malin S, et al. Expression of the coxsackie and adenovirus receptor in human astrocytic tumours and xenografts. Int J Cancer 2003; 103: 723-729.
12. Huang KC, Altinoz M, Wosik K, et al. Impact of the coxsackie and adenovirus receptor (CAR) on glioma cell growth and invasion: requirement for the C-terminal domain. Int J Cancer 2005; 113: 738-745.
13. Jagannathan J, Prevedello DM, Dumont AS, et al. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme. Neurosurg Focus 2006; 20: E8.
14. Lote K, Stenwig AE, Skullerud K, et al. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998; 34: 98-102.
15. Oberndorfer S, Schmal T, Lahrmann H, et al. The frequency of seizures in patients with primary brain tumours or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna. Wien Klin Wochenschr 2002; 114: 911-916.
16. Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011; 77: 1156-1164.
17. Knupfer MM, Pulzer F, Schindler I, et al. Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Anticancer Res 2001; 21: 347-351.
18. Fan S, Maguire CA, Ramirez SH, et al. Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods 2005; 125: 23-33.
19. Segura-Pacheco B, Avalos B, Rangel E, et al. HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo. Genet Vaccines Ther 2007; 5: 10.
20. Lin KT, Yeh SH, Chen DS, et al. Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. J Biomed Sci 2005; 12: 803-813.
21. Wedel S, Hudak L, Seibel JM, et al. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. Prostate 2011; 71: 722-735.
22. Hoti N, Chowdhury W, Hsieh JT, et al. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther 2006; 14: 768-778.
23. Eyal S, Yagen B, Sobol E, et al. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004; 45: 737-744.
24. Stander M, Dichgans J, Weller M. Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. J Neurooncol 1998; 37: 191-198.
25. Bobustuc GC, Baker CH, Limaye A, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 2010; 12: 917-927.
26. Balvers RK, Kloezeman JJ, Heijsman D, et al. Genotypic profiling of serum-free primary malignant glioma cultures reveals EGFR/PTEN aberrations as a prerequisite for successful propagation. Neuro Oncol 2011; 13: 166.
27. Karkar KM, Thio LL, Yamada KA. Effects of seven clinically important antiepileptic drugs on inhibitory glycine receptor currents in hippocampal neurons. Epilepsy Res 2004; 58: 27-35.
28. Loscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res 1993; 18: 485-502.
29. Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003; 45: 661-671.
30. Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 2000; 42: 281-285.
31. Vajda F, Williams FM, Davidson S, et al. Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital. Clin Pharmacol Ther 1974; 15: 597-603.
32. Patsalos PN. Pharmacokinetic profile of levetiracetam: towards ideal characteristics. Pharmacol Ther 2000; 85: 77-85.
33. Lee J, Kotliarova S, Kotliarov Y, et al. Tumour stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumours than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
34. Shao Y, Gao Z, Marks PA, et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004; 101: 18030-18035.
35. Lee SC, Magklara A, Smith CL. HDAC activity is required for efficient core promoter function at the mouse mammary tumour virus promoter. J Biomed Biotechnol 2011; 2011: 416905.
36. Sachs MD, Ramamurthy M, Poel H, et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 2004; 11: 477-486.
37. Inagaki A, Soeda A, Oka N, et al. Long-term maintenance of brain tumour stem cell properties under at non-adherent and adherent culture conditions. Biochem Biophys Res Commun 2007; 361: 586-592.
38. Nguyen TL, Abdelbary H, Arguello M, et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 2008; 105: 14981-14986.